Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
Gilead Sciences · HIV-1-infection
Phase 2 / Phase 3
Active, not recruiting
689
2025-10
Industry sponsor intelligence
Gilead SciencesClinical Pipeline.
Lead-sponsor view of Gilead Sciences's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 1
- Completed
- 1
- Results posted
- 1
- Avg enrollment
- 707
Pipeline overview
Programs by phase and activity.
Velocity
Gilead Sciences trials by start year
Study start year · indexed snapshot
Development
Trials by phase
3phase labels
Early Phase 10
Phase 10
Phase 21
Phase 32
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Enfuvirtide → | 2 | 0 | 1 | 2 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
Gilead Sciences · HIV Infection
Phase 3
Completed
724
2016-05
Search sponsor records
All Gilead Sciences studies.
This page groups studies where Gilead Sciences is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT05502341Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated RegimenOct 14, 2025NCT00708162Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirMay 30, 2016